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Abstract
The purpose of this research and systematic literature review is to determine if there is a
measurable difference of effectiveness in medication assisted treatment (MAT) in patients with
oxycodone and heroin use disorders, retention in treatment, and sustained sobriety. In this
review, the databases searched included CINAHL, Clinical Key, and Embase. A variety of key
terms and MeSH terms were used to define a set of literature discussing the topic. The works
chosen for review were published between 2015 and 2019 were peer reviewed, and included
randomized control trials, pilot studies, and systematic reviews. Sources that were excluded,
included those published prior to the year 2015, had poor study design or no useful statistical
data. For this review, 16 resources were selected. Much of the research presented show proven
evidence of the efficacy and usefulness in MAT for the treatment of opioid use disorder.
However, much of the research does not seem to directly compare the statistical difference in
effectiveness of MAT for oxycodone and heroin use disorders, rather they are both put together
in one group. The differences become apparent when adjunctive therapies are added. These
therapies include; inpatient and outpatient rehabilitation, the type of medication being used, and
the addition of cognitive behavioral therapy (CBT). Consequently, more research is still needed
to be done in order to definitively determine if MAT is more effective for treating oxycodone use
disorder or heroin use disorder.
Keywords: medication assisted treatment, oxycodone, heroin, oxycodone use disorder, heroin
used disorder, opioids, opioid use disorder.
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Introduction
Opioid-use disorder is a major concern in the United States leading to an increased
number of overdose deaths per year from both prescription and illegal opioids. Roughly half of
opioid use deaths are attributable to prescription medications like oxycodone with other half
from illegal drugs such as heroin. Over prescribing of opiates for pain management is one of the
major contributors to opioid deaths. The ease of availability of illegal drugs like heroin has also
added to the problem. Medication Assisted Treatment (MAT) was developed for this problem
and the same medications can be used for both prescription and illegal opioid addiction. The
purpose of this study is to compare the effectiveness of MAT programs at treating opioid-use
disorders in both oxycodone and heroin users and determine if there is a difference in sustained
sobriety and compliance.
Statement of the Problem
Medication assisted treatment programs have a negative stigma associated with them.
Many providers believe that the use of medications like buprenorphine and naltrexone are merely
substituting one opiate for another. MAT medications are opiates, but they are only partial
agonists of the mu receptors compared with oxycodone and heroin which are complete agonists.
The partial agonists activate the receptors without the euphoria from the complete agonists, and
also satisfy cravings and withdrawal symptoms. MAT has been proven to be effective. Providers
need to be informed on which patients are going to respond better to treatment with medications
and which patients need alternate forms of treatment.
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Research Question
In opioid addicted patients, is MAT a more effective therapy to achieve sobriety and
compliance for patients addicted to prescription opioids, such as oxycodone, or more effective
for those addicted to a street opioid, like heroin?
Research Methods
To prepare this article, the author searched CINAHL, Clinical Key, and Embase
databases and selected articles to provide a broad overview of opioid use disorders, including
which medications are used in treatment, how these medications are effective, and how using
these medications along with other forms of therapy can be helpful in maintaining sobriety. The
search included key terms and MeSH terms: medication assisted treatment, oxycodone, heroin,
oxycodone use disorder, heroin used disorder, opioids, opioid use disorder. The search included
articles from the past 4 years (2015-2019). Studies were included if they focused on safety and
effectiveness of medication assisted treatment for both prescription opioids and illicit opioids to
mainly focus on heroin as the illicit drug. Other studies included in this research encompassed,
therapies to maintain sobriety once treatment with medication had begun. The literature focus of
this investigation, because of their high quality, became the numerous newly published projects
and studies.
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Safety and Efficacy of Medication Assisted Treatment
Opioid use disorder (OUD) has become a major epidemic and has affected many
populations across the United States and especially in rural areas, where there are not as many
healthcare facilities to provide service (Kawasaki, 2019). The medications used in treatment are
buprenorphine, naltrexone, and methadone. Medication assisted treatment (MAT) is medical
treatment used to help individuals with opioid use disorder. Unfortunately, the number healthcare
providers participating in the treatment programs is very low, likely because they have a negative
stigma surrounding it. Primary care providers are on the front lines of the overdose epidemic, but
the demand for treatment far exceeds the capacity to treat. Certain projects, like project ECHO,
were developed for this supply and demand problem. The mission was to provide and expand
comprehensive, patient-centered and innovative evidence-based treatment to individuals with
substance use disorders by using four core principles: (1) use technology to leverage scarce
resources; (2) share best practices to reduce disparities; (3) employ case-based learning to master
complexity; (4) monitor outcomes to ensure benefit (Kawasaki, 2019).
The project connected primary care sites and hospital systems in rural areas through a
combination of Hub and spoke, bridge clinic services provided at the Hub, peer recovery
services, and layered emergency departments. To investigate the efficacy, a study was conducted
to review medications used in the treatment and to determine retention rates. The initial trial had
180 patients with 127 started on buprenorphine, 9 on extended-release naltrexone, and 30 on
methadone treatment. The first 6 months showed a treatment retention rate of 43% of the
buprenorphine patients, 11% of the extended-release naltrexone patients, and 63% of the
methadone patients (Kawasaki, 2019).
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This study along with the development of project ECHO, had many other components
other than merely the medications the patients were prescribed. It is recognized that in order for
treatment of OUD to be successful, four key components were necessary. These components are
comprised of; pharmacological therapy, psychosocial services, integration of care, and education
and outreach (Kawasaki, 2019).
In another article by Oesterle et al. (2019), a comparison of all three FDA-approved
medications for treatment of OUDs (buprenorphine, naltrexone, and methadone) appear to offer
evidence of efficacy. One study found that individuals randomly assigned to either methadone or
buprenorphine showed that 33.2% had achieved 5-year abstinence from heroin, only 20.7% had
remained abstinent from both heroin and other opioids. The two treatment groups were compared
and showed that after 5 years, opioid use at follow-ups were higher among participants
randomized to buprenorphine, relative to methadone. However, both groups were more
successful than the no-treatment group, and mortality was not different between the 2 groups.
Unfortunately, there was no data available from the naltrexone group for the 5-year follow-up
(Oesterle, 2019).
Opioid use disorder treatment is a long-term commitment which can take years and, in
some cases, indefinite medication and cognitive assistance to remain abstinent. For those who
become pregnant while suffering from OUD, continuing with MAT is a risk versus reward
scenario. Opioids have an effect on the fetus and after delivery can cause neonatal abstinence
syndrome (NAS) after delivery. MAT medications when compared to heroin and oxycodone
have much lower opioid receptor agonist activity but hold a higher affinity to the receptor as
well. This means, cravings will be satisfied without the euphoria felt with complete opioid
receptor agonists.
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In a study by Gala et al. (2019), 257 pregnancies were followed after having antenatal
exposure to buprenorphine from 2015-2018. The study was performed at a single center to
determine the relationship between buprenorphine dose and neonatal abstinence syndrome
incidences. Buprenorphine has been the preferred medication for opioid maintenance therapy in
pregnancy in comparison with other medications. No major congenital anomalies occurred
during the study. Doses at delivery were divided into three groups: low (0-10 mg), medium (1120 mg), and high (>20 mg) dose groups. Correlations between delivery dose and neonatal
outcomes of interest were analyzed. A statistically significant increase in NAS duration was
found in the high dose group (P¼0.06) and decrease in birthweight in the medium dose group
(P¼0.002) were noted in neonates of mothers with positive urine drug screens at delivery. No
statistically significant difference was seen among other neonatal outcomes, such as APGAR
scores and gestational age at delivery by buprenorphine dose and urine drug screen status.
Similar trends, in the small dose group, were noted by not statistically significant (Gala, 2019).
No major complications occurred in the study and at lower doses, lower incidences of NAS were
observed. It was found that if the dose is gradually decreased prior to delivery, the incidence of
NAS also lowers making it safer for the neonate (Gala, 2019).
Patients with Opioid Use Disorder Involving Oxycodone
A large number of individuals who suffer from opioid use disorder involving prescription
pain medication, such as oxycodone, have chronic pain. There are also a lot of individuals that
use prescription pain medications recreationally including adolescents. Along with the
recreational use of prescription opioids, there is a high correlation with mental health issues, such
as depression and anxiety.
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In an article by Clayton et al. (2019), a survey of 14,765 high school students in grades 912 was performed in 2018. A questionnaire was released to assess the lifetime, nonmedical use
of prescription opioids (NUPO) with the responses listed as “zero times” or “one or more times”.
This questionnaire was paired with health behaviors and experiences such as substance use,
violence victimization, suicidal thoughts and behaviors, sexual behavior and others, to determine
if there was a correlation between those factors and NUPO. The overall prevalence of NUPO
among high school students was 14%. The prevalence of NUPO varied significantly by grade
(p<0.0001) and sexual identity (p<0.0001). In each of the adjusted models, students who
engaged in NUPO had a significantly greater likelihood of also engaging in each substance use
behavior, than students without NUPO (Clayton, 2019).
Students who engaged in NUPO were significantly more likely also to have reported
being bullied on school property or threatened or injured with a weapon on school property than
students without NUPO. Students who engaged in NUPO also were more likely to experience
each of the three suicide behaviors than students without NUPO (ranging from seriously
considering suicide to attempting suicide). Students who engaged in NUPO were more likely to
be at increased risk for sexual behaviors ranging from not using a condom, nor a highly effective
hormonal contraceptive method during last sexual intercourse, to having 4 or more sexual
partners. It was also found that students who engaged in NUPO were 5-6 times more likely to
have poor academic performance and more likely to have experienced persistent feelings of
sadness and hopelessness (Clayton, 2019).
A study was performed from June 2015 to June 2016 in an article by Gardner et al. 2019,
to predict opioid use disorder in patients with chronic pain presenting to an emergency
department. The goal was to categorize these individuals for chronic pain issues as either “opioid
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use disorder” or “nonopioid use disorder” patients. This was determined by a series of questions,
physical exams and past medical histories that were performed on 89 patients to help categorize
the participants. The results found that 45 of the 89 participants had OUD. Those 45 participants
also had a higher proportion of documented or reported psychiatric diagnoses (p=0.049),
preference of opioid treatment (p=0.005), current oxycodone prescription (p=0.043), borrowed
pain medicine (p=0.004) and non-authorized dose increase (p<0.001). The state prescription
monitoring database revealed the OUD group to have increased number of opioid prescriptions
(p=0.005) and pills (p=0.010). Participants who borrowed pain medicine and engaged in nonauthorized dose increase were 5.2-6.1 (p=0.025), (p=0.001) times more likely to have OUD.
Ultimately, it was determined that patients with chronic pain categorized as having an OUD have
distinguishable characteristics and associated mental health behaviors (Gardner, 2019).
Patients with chronic pain and their severity of the pain can be hard to judge and patients
with OUD become even more sensitive to pain after a period of time, making treatment and
stopping opioids a tough battle. A pair of studies by Paulus et al. (2019), discussed pain severity
and prescription opioid misuse among individuals with chronic pain and the moderating factor of
alcohol use. The goal of the studies was to examine the relationship between pain and
prescription opioid misuse and the moderating role of alcohol use severity, using data from
online samples of individuals with chronic pain. Both studies revealed that the association,
between pain severity and opioid misuse was significant for those with high alcohol scores. The
findings suggest that alcohol use severity exacerbates the pain-opioid association such that pain
is positively associated with opioid misuse only among those with relatively greater alcohol use.
Other factors were also considered in the studies which included age, level of education, and
depressive symptoms. Including the interaction term of average pain severity and alcohol use in
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step three significantly improved model fit (F (7356) =29.00, p < .001, ΔR2 =.03), and the
interaction term was a significant predictor (B = .16, SE = .04, p < .001). Examining the simple
slopes revealed that those with high AUDIT total scores (+1SD; B=1.50, SE =.38, p =.001), but
not low (-1 SD; B=-.26, SE = .33, p =.430) evidenced a statistically significant association
between average pain severity and opioid misuse. The JN technique revealed that the effect of
pain severity on opioid misuse was significant only for those with an AUDIT of 4.84 or greater
(34.34% of the current sample). It was revealed that greater depressive symptoms related
significantly and strongly to greater opioid misuse in both samples (Paulus, 2019).

Patients with Opioid Use Disorder Involving Heroin
The opioid use disorder epidemic has become a major problem in the last few decades.
The number of individuals that need treatment greatly outnumbers the capacity of healthcare
providers that can supply the necessary services. Heroin use has been a major issue in the opioid
epidemic and an article by Brighthaupt et al. (2019), studied the trends in adolescent heroin use
in some of the largest urban cities in the United States from 1999-2017. The goal of the study
was to determine if the trend of heroin use has remained low and stable or has increased
(Brighthaupt, 2019).
The study was conducted by surveying high school students in grades 9-12 regarding the
use of heroin, using logistic regression to test for linear and quadratic trends. It included nine of
the largest cities in the U.S. The study identified increases in heroin use over time in the majority
of the cities over time, which suggests the use among adolescents is increasing (Brighthaupt,
2019). With the increase in heroin and other opioids, MAT treatment with medication alone
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cannot solve the problem. Many other factors contribute to the success MAT and incorporating
those aspects is where success will be found.
In a study by Colledge et al. (2017), exercise was assessed to monitor the feasibility and
acceptance as an adjunctive therapy in patients receiving outpatient treatment for heroin use
disorder. The study was a pilot randomized trial of 50 were selected but only 24 individuals
willing to take part in the study. The results revealed 92.3% of the participants were compliant or
semi-compliant with the exercise condition and were able to exercise at a high intensity level.
The other 7.7% of the participants did not follow through with the exercise. Although the sample
size was small and participants were allowed to freely select the type and intensity of exercise
triggering a number of variables, it was concluded that exercise intervention is a feasible and
accepted supplementary therapy to heroin-assisted therapy. The mental aspect, however,
specifically mood was increased in all the participants that took part in any type of exercise.
Mood is a very important factor to consider in patients in treatment for opioid use disorder.
Along with the mental aspect of MAT, dose adjustments need to be monitored closely to
assess how well other symptoms are being controlled such as pain, cravings, and withdrawal
symptoms. In an article by Mannaioni et al. (2018), a randomized clinical trial was used to assess
how methadone dose adjustments and monitoring of the plasma r-methadone levels of heroin
users can be used for therapeutic outcomes. The goal was to determine if there was a significant
improvement in retention and therapeutic outcome in patients being treated with methadone, by
adjusting the oral methadone dose in order to reach a target plasma r-methadone level of 80-250
ng/mL (Mannaioni, 2018).
A total of 308 patients already in methadone maintenance treatment for heroin use
disorder were participants in the study. Participants were randomized into two groups: the first
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(controls) received a daily methadone dose, which was previously selected and adjusted on
clinical basis by the specialist physician in charge in each participating center. The second group
(treated patients) had their daily methadone dose adjusted on the basis of plasma r-methadone
concentrations. The belief was that if the patient’s plasma r-methadone level was stabilized by
constantly changing the daily dose to remain at a certain level it would result in higher retention
and better therapeutic outcomes. After six months of the study, 91% of the control group and
81% of the treated patient group were still participating in treatment, indicating that, the constant
dose adjustments to stabilize the plasma r-methadone level did not improve retention in
treatment. After 12 months there was no significant differences between the two groups. When
retention in therapy was evaluated, both groups reported a significant decrease in heroin use.
Although the constant dose adjustment theory was not a success, it was determined that patients
with optimal plasma r-methadone levels at the beginning of study achieved higher retention rates
and therapeutic outcomes than those patients with levels outside the optimal range.
Compliance and Sobriety During and After Treatment
Compliance of MAT and maintaining sobriety is not just simply taking the prescribed
medication appropriately. There are many factors that need to be taken into account and it can be
an everyday battle for some people. In an article by Huhn et al. (2017), a study was performed to
look at the relationship between treatment accessibility and preference amongst out-of-treatment
individuals who have an opioid use disorder. The study had 357 participants that were surveyed
regarding demographics, insurance status, attitudes toward OUD and self-reported symptoms of
OUD. The treatment options participants were most likely to use during their recovery were oneon-one counseling (53.8%) 12-step groups (41.2%) and physician visits (32.8%) (Huhn, 2017).
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Participants were asked which types of treatment they would refuse or which treatments
they felt did not work. The three treatments assessed least negatively were: sober living/half-way
houses (33.1%), methadone clinics (32.2%), and 12-step groups (26.6%). The least endorsed
option was one-on-one counseling (5.6%). When put into two groups; one being with insurance
and two without insurance, the results of treatment options varied. The cost of medication was
the largest deciding factor and participants without insurance endorsed less perceived availability
for treatment options compared to participants with insurance. It was determined that out-oftreatment opioid users were particularly interested in counseling-based services and medical care
that could be attained from a primary care provider. Results suggest that insurance coverage and
perceived access to OUD treatment modalities influences where out-of-treatment opioid users
might first seek treatment. Understanding the factors that shape treatment preferences is critical
in designing early interventions to effectively reach each of these populations (Huhn, 2017).
In another article by Ober et al. (2018), a study was done to assess patient predictors of
substance use disorder treatment initiation in primary care. In clinics that had recently
implemented motivational-interviewing and cognitive behavioral therapy (CBT) – based brief
treatment and MAT for patients identified with an OUD were involved in the study. The major
questions that were asked were: What predisposing, enabling/inhibiting resources and
need/severity factors predict initiation of CBT for an OUD in primary care (Ober, 2018).
In the multivariate model examining factors associated with initiation of CBT, being
“other” or “multiple” races compared with being White, being homeless and having been
arrested within 90 days of baseline, were associated with significantly lower odds of initiating
CBT. Greater self-stigma, and having received the collaborative care study intervention were
associated with higher odds of initiating CBT. In the multivariate model examining patient
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factors associated with initiating MAT include; older age, female gender, having a diagnosis of
heroin use disorder compared with having a diagnosis of alcohol dependence only and having
received at least one session of CBT were associated with higher odds of initiating MAT (Ober,
2018). Mental health is one of the biggest factors that affect individuals with OUD and even just
one session of counseling has shown to improve outcomes.
An article by Prieto et al. (2019), assessed over 3200 patients with an OUD that were
receiving MAT to measure engagement and adherence to treatment. The results showed that 32%
were in the medication assisted treatment stage, and of those, 60% were adherent to treatment. In
another group 78.4% adhered to treatment for at least 90 days and 52.3% for more than one year.
Among patients who received MAT, less than one third were adherent for more than one year
(Prieto, 2019). The treatment was working, but MAT alone cannot maintain sobriety. Many more
factors must be in place for MAT to be successful for long-term sobriety.
Medicated assisted treatment works better when it is combined with a structured facility
like a 12-step based professional treatment center. An article by Klein et al. (2019), examined the
feasibility of and initial impact of combining these 2 models for individuals with OUDs. The
study sought to determine whether patients self-selecting into a treatment program based on a 12step philosophy would elect to use MAT and if so, what initial outcomes might result (Klein,
2019).
Additionally, researchers tracked patients to determine which recruited participants were
successfully inducted on either form of naltrexone or buprenorphine, or no medication; and
among patients who took buprenorphine, which patients continued taking it as a maintenance
medication beyond the withdrawal period. Injectable naltrexone patients had a higher follow-up
rate (92%) than buprenorphine patients (76%), the oral naltrexone patients (67%) and the no
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medication patients (62%) (p<0.001). Of those patients, 81% reported compliance with their
medications. Injectable naltrexone compliant patients were significantly more likely to be
abstinent at 6 months than oral naltrexone compliant, buprenorphine compliant, and all other
patients (Klein, 2019).
A significant difference emerged for the total number of co-occurring mental health
disorders; buprenorphine patients and oral naltrexone patients had a significantly higher number
of mental health disorders than the no medication patients. Buprenorphine patients had
significantly higher scores on the desire and intention to drug use scale than injectable naltrexone
patients and no medication patients. Patients who ultimately chose to maintain on buprenorphine
reported significantly higher levels of craving than both naltrexone groups and the no medication
group at treatment admission (p<0.001) (Klein, 2019).

Discussion
The safety and efficacy of medicated assisted treatment medications has been proven to
be safe and effective. Buprenorphine, in the more commonly prescribed form, has naloxone
combined with it, which induces withdrawals if taken any other way than how it is prescribed,
which is orally. The naloxone prevents patients from experiencing euphoria when injected and
patients are less likely to try to abuse the medication other than for its prescribed purpose. There
is still a negative stigma about the effectiveness of the medications of many providers. They
believe that MAT is merely substituting one opioid for another. MAT has shown to be effective
and the providers that are against it, likely need more education about the subject to understand
what MAT really incorporates. Buprenorphine has also been shown to be effective during
pregnancy. The doses should be lowered as much as possible but remain high enough so it is still
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effective for the mother. Studies have shown, no major birth defects from buprenorphine. The
newborn may go through withdrawals for a period of time after birth but using buprenorphine is
much safer than a full agonist drug like heroin or oxycodone (Gala, 2019).
Patients with opioid use disorders involving oxycodone or heroin share many
characteristics. A large proportion of this population will use whichever opioid they can obtain to
satisfy cravings or relieve pain and become addicted. For these patients, it has been found that
most of them suffer from mental health issues as well, such as depression and anxiety. The use of
heroin and oxycodone only increase these behaviors compounding the issue (Tsui, 2016).
Medication assisted treatment can be effective for both types of OUD from prescription
medications to heroin. The transition from using to recovery with a change in medication can be
the hardest for the patient, and finding the right dose to start with is precarious. Most patients
choose to start with buprenorphine as it is convenient and easily administered over naltrexone or
methadone. Methadone is very effective but is not convenient for the patient. Methadone is
administered once a day but the patient needs to go to the clinic every day for the dose to be
administered. For those who utilize this method and stay adherent to it, they do very well, but
most choose to stop going. This typically ends in relapse or the patient may find another route to
get prescribed buprenorphine or naltrexone.
The research question asked if there is a measurable difference in the effectiveness of
MAT comparing oxycodone and heroin users and achieving sobriety and compliance in MAT
programs. From the research that was found and utilized, there does not seem to be a measurable
difference. The research revealed that many other factors contribute such as homelessness, age,
race, depression and anxiety, level of education and others. Almost all patients who suffer from
OUD have some level of mental health behavior like depression. MAT is effective for both types
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patients, including patients suffering from chronic pain. There does not appear to be a significant
statistical difference of effectiveness between drugs.
In order for a patient with OUD to be successful with MAT and achieve long-term
sobriety, each patient must be treated as an individual case. Each situation is different and there
are more factors than solely treating an addiction with a medication. Some patients need more
structure like an inpatient treatment facility to begin their recovery and others do well with just
outpatient to start. It has been revealed that almost all patients with OUD however, do better in
the long-term if they receive some sort of cognitive behavioral therapy. CBT improves adherence
to therapy and maintenance of sobriety past the 1-year mark (Klein, 2019).
In order for all individuals suffering from OUD and want to start treatment,
demographics, location, cost of medication, and even having a car or some mode of
transportation are important factors that need to be reconciled. Many patients in rural areas that
need to see a primary care provider must travel up to 2 hours or more to get to their provider who
participates in MAT programs. These are barriers that patients face every day, which complicate
and contribute to the opioid crisis. More providers need to utilize MAT programs. There is a
large population of patients with unmet needs which could be met if more MAT programs were
available. With all the information provided through research, it is ultimately up to the patient,
whether or not all the treatment modalities provided will help. If the patient does not want to be
treated, MAT will not work until they reach the point of wanting help.
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Applicability to Practice
The information gathered with this research is very valuable as a provider. MAT is a
great way to help reduce the opioid crisis and will help in making better choices, and be more
conscientious about prescribing opioids to patients who need them and what to watch out for.
MAT is also another tool to build your patient numbers and help the healthcare facility bring in
more patients and money.
If more providers participated in MAT programs, at their healthcare facilities, the patients
would have another option for their required care. By seeing these types of patients, it will
become easier to identify the patients that come in requesting painkillers, if they are seeking
opioids or if they really are in pain and need help. Asking astute questions and assessing patients
with a thorough history and physical is key to identifying these patients and also being able to
identify if they have any mental health behaviors that are contributing to their situation. The
research and information included, will make each provider a better provider and add to their
abilities to treat these patients appropriately and provide the quality medical treatment including
mental health specialist referrals when required.
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